Eurobio Scientific extends its family of proprietary PCR tests to allow the identification of SARS-CoV-2 variants
09 Marzo 2021 - 7:30AM
Eurobio Scientific extends its family of proprietary PCR tests to
allow the identification of SARS-CoV-2 variants
EUROBIO Scientific extends its family of
proprietary PCR tests
to allow the identification of SARS-CoV-2
variants
- Proprietary PCR test available immediately
- One of the first tests able to identify the presence of
variants presenting a risk of immune escape
Paris, March 9, 2021 – 7:30 a.m.
Eurobio Scientific (FR0013240934, ALERS,
PEA-PME eligible), a leading French group in in vitro
medical diagnostics and life sciences, announces the launch of a
new proprietary test, EurobioPlex SARS-CoV-2 Variants, Detection
& Typing (EBX-044), a real-time multiplex PCR* test for the
detection and typing of different variants of the SARS-CoV-2
coronavirus.
EBX-044 is a kit developed and manufactured in
France by Eurobio Scientific. It allows the detection and screening
in two PCR wells of the four currently predominant variants:
British, South African, Brazilian and Japanese-Brazilian. It
identifies several mutations, including the E484K mutation, found
in South African and Brazilian variants, which is believed to be
involved in the escape of the virus from the immune system. In
addition, it makes it possible to distinguish the South African
variant carrying the A80D mutation from the Brazilian variants.
This test is integrated with the other tests in the EurobioPlex
family, on open instruments that are used in large hospital and
private laboratories.
Pending CE marking, which should take place in a
few days, EBX-044 is on the list of RUO (Research Use Only) tests
already marketed as part of the pandemic emergency.
At the same time, Eurobio Scientific is
registering with French health authorities the AllPlex SARS-CoV-2
Variant 1 Assay test from its partner Seegene (South Korea). This
test, also developed for the detection of SARS-CoV-2 variants, is
intended to be used specifically on Seegene's automated and
dedicated platforms.
With these tests adapted to the new variants,
Eurobio Scientific continues to provide in real time the tools
necessary to manage the current pandemic and its evolution. With
the arrival of vaccines, and the new risks presented by the E484K
mutation, EBX-044 is one of the first tests to closely monitor the
spread of variants that could escape the immune system. It thus
gives health officials the indicator they need to adapt the
pandemic exit strategy in real time.
* The "Polymerase Chain Reaction" (PCR) is a
method based on the selective multiplication of target DNA
sequences, which makes it possible to detect specific DNA sequences
present in a product.
Next financial meeting2020 annual results:
April 14, 2021 (after market close)
About Eurobio Scientific
|
Eurobio Scientific is a key player in the field of specialty in
vitro diagnostics. It is involved from research to manufacturing
and commercialization of diagnostic tests in the fields of
transplantation, immunology and infectious diseases, and sells
instruments and products for research laboratories, including
biotechnology and pharmaceutical companies. Through many
partnerships and a strong presence in hospitals, Eurobio Scientific
has established its own distribution network and a portfolio of
proprietary products in the molecular biology field. The Group has
approximately 165 employees and three production units based in the
Paris region, in Germany and in the United States, and several
affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany
and Utrecht in The Netherlands. For more information, please
visit : www.eurobio-scientific.com The company is publicly
listed on the Euronext Growth market in Paris Euronext Growth BPI
Innovation, PEA-PME 150 and Next Biotech indices, Euronext European
Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 -
Reuters: ALERS.PA - Bloomberg: ALERS:FP |
|
Contacts |
|
Group Eurobio Scientific Denis Fortier, General
Manager Hervé Duchesne de Lamotte, General Manager Tel. +33(0) 1 69
79 64 80 |
Calyptus Mathieu Calleux / Gregory Bosson
Investors relations Tel. +33(1) 53 65 68 68
eurobio-scientific@calyptus.net |
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Apr 2023 a Apr 2024
